Paper Retractions Unveil China Academic Fake Review Scams
This article was originally published in PharmAsia News
Executive Summary
Out of 43 papers retracted by BioMed Central due to an inappropriate and manipulative peer review process, 41 are from China, involving 38 top hospitals around the country. Some of the affected research papers relate to drugs, including an anti-platelet agent and a novel compound for hepatocellular carcinoma.